Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 USD | -1.36% | -2.69% | +11.86% |
04/03 | North American Morning Briefing : Stock Futures -2- | DJ |
28/02 | Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 224
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
T-Cell Therapies
100.0
%
| 85 | 100.0 % | 0 | 100.0 % | -99.85% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 85 | 100.0 % | 0 | 100.0 % | -99.85% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 01/21/01 |
Charles Newton
DFI | Director of Finance/CFO | 53 | 01/21/01 |
Stephen Hill
COO | Chief Operating Officer | 53 | 01/19/01 |
Gary Lee
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/22/31 |
Richard D. Goold
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/19/01 |
Ellen Rose
IRC | Investor Relations Contact | - | 01/21/01 |
Matthew Lang
LAW | General Counsel | 48 | 05/23/05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 01/21/01 |
Robert Nelsen
BRD | Director/Board Member | 60 | 01/18/01 |
Otis Brawley
BRD | Director/Board Member | 64 | 01/21/01 |
William Rieflin
BRD | Director/Board Member | 64 | 01/20/01 |
Richard Klausner
CEO | Chief Executive Officer | 72 | 01/18/01 |
Director/Board Member | 63 | 01/18/01 | |
Hans Bishop
BRD | Director/Board Member | 59 | 01/18/01 |
Elizabeth Nabel
BRD | Director/Board Member | 72 | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 254,936,784 | 206,999,293 ( 81.20 %) | 0 | 81.20 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CERo Therapeutics Holdings, Inc.
3.35% | 499,999 | 3.35% | 1,534,997 $ |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.86% | 553M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- LYEL Stock
- Company Lyell Immunopharma, Inc.